|
CHECK OUT OUR APRIL 1ST ISSUE
The drug, approved in China, appears to have the same safety and efficacy profile of anti-VEGF medications available in the U.S., but may allow for reduced dosing frequency.
» Click for more on the novel drug
|
|
In his latest editorial, Peter J. McDonnell, MD, chief medical editor of Ophthalmology Times, takes a stab at #thedress, and what the Internet phenomenon really means. » Read the column
|
|
This month's simultaneous meeting of ASCRS and ASOA will convene in San Diego from April 17 to 21. » Tips on the meeting
|
|
Advice for how clinicians can market their practice to be chosen as a research study site. » Click for the advice
|
|
|
Like
Tweet
